Skip to main content
Back to projects
CRO & Clinical Trial Support2024

Phase II RCT Statistical Support — Empagliflozin in Non-Diabetic CKD

End-to-end statistical deliverables for a 180-patient multicenter Phase II RCT across 5 sites in the UAE and Saudi Arabia. Covered full SAP authoring, CDISC-compliant ADaM datasets, randomization scheme, pre-planned interim analysis, and final regulatory-grade report.

Phase II RCT Statistical Support — Empagliflozin in Non-Diabetic CKD

Project highlights

Phase II
Trial phase
180
Sample size
5
Sites
MMRM
Primary model

Methods & Tools

Phase II RCTStatistical Analysis Plan (ICH E9)MMRM (SAS PROC MIXED)Multiple-imputation sensitivitySurvival analysisSAS 9.4R (nlme, emmeans)CDISC SDTM/ADaM · Pinnacle 21
The challenge

A Phase II chronic-kidney-disease RCT required a regulator-grade Statistical Analysis Plan and a primary analysis robust to missing data across 5 sites. The longitudinal endpoint had to be modeled without bias from informative dropout.

What we did

We authored the SAP to ICH E9, implemented a mixed-model-for-repeated-measures primary analysis, and stress-tested every conclusion with pre-specified sensitivity analyses.

01

Authored the ICH E9(R1)-aligned Statistical Analysis Plan, defining estimands, the primary model, multiplicity control, and the missing-data strategy before database lock.

02

Fitted the primary MMRM (SAS PROC MIXED) on the longitudinal endpoint across 180 participants with covariate adjustment and an unstructured covariance, independently double-programmed in R (nlme).

03

Ran pre-specified sensitivity analyses (multiple imputation, tipping-point) and time-to-event models, and produced CDISC SDTM/ADaM datasets validated with Pinnacle 21.

What we delivered

Regulator-grade Statistical Analysis Plan with clearly defined estimands.

Primary MMRM results, sensitivity analyses, and a full TLF package.

Validated CDISC SDTM/ADaM datasets with double-programming QC.

Methodology & Quality Assurance

Statistical Analysis Plan finalized and signed off before database lock.

Primary analysis independently double-programmed in SAS and R for agreement.

Robustness confirmed with pre-specified sensitivity and tipping-point analyses.

Datasets validated with Pinnacle 21 against CDISC standards.

Project gallery
Phase II RCT Statistical Support — Empagliflozin in Non-Diabetic CKD
Phase II RCT Statistical Support — Empagliflozin in Non-Diabetic CKD
Phase II RCT Statistical Support — Empagliflozin in Non-Diabetic CKD

We were running a Phase II trial on empagliflozin in non-diabetic kidney patients, and the statistics were honestly beyond our own team. They handled the randomisation and the analysis plan from the beginning, and when the reviewers asked difficult questions, the answers were already there in the report. This saved us a lot of time.

F
Dr. Faisal Al-Qahtani
Principal Investigator, CKD Trial — Riyadh

Have a project to register?

Submit your project in the dashboard and we’ll map the analysis plan, deliverables, and timeline.